Maintenance PARP inhibition following chemotherapy for metastatic urothelial carcinoma
In the ATLANTIS rucaparib arm, the PARP-inhibitor rucaparib as maintenance therapy, following platinum-based chemotherapy, shows an extended progression free survival for patients with metastatic urothelial carcinoma. In this MEDtalk, Dr Simon Crabb, Associate Professor in Medical Oncology, presents the trial and the data.
Get access to the article
If you are a doctor, nurse, or other health professionals, you can access the entire article by creating a profile on BestPractice Nordic.